RE:New hereGazzman,
It is a long long story. I recommend listening to the recent conference call and reading the corporate presentation.
The targets you have seen barely reflect the potential that could be realized within 1-2 years. The low price reflects decades of waiting for a one product company to turn that product into a revenue strea,
Back 5-6 years ago, the company had an entirely different focus, on pela directly killing cancer cells. Now science and immuno-oncology has evolved and the array of applications in combination with other agents is practically unheard of.
WC